---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-127535"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:51:39.553105+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ResMed Q3 revenue up 12% to $864.5M; non-GAAP EPS $1.32, up 2% YoY

## Summary
- Revenue $864.5M (+12% YoY); constant currency growth 14%.
- GAAP diluted EPS $1.22 (up from loss of $0.54); non-GAAP diluted EPS $1.32 (+2%).
- Gross margin contracted 140 bps to 56.8%; non-GAAP gross margin contracted 150 bps to 58.1%.
- Board declared $0.42/share dividend, record May 12, payable June 16, 2022.
- CEO cites strong sleep/respiratory demand but supply chain disruptions limit ability to meet demand.

## SEC filing metadata
- accession: 0001193125-22-127535
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312522127535/0001193125-22-127535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312522127535/d319859d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-127535
- JSON: https://secwatch.observer/filing/0001193125-22-127535.json
- Plain text: https://secwatch.observer/filing/0001193125-22-127535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.